NCT06160271View on ClinicalTrials.gov

Study of Liver Fibrosis Stage Assessment by Fibroblast Activation Protein Imaging in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

September 1, 2026

Study Completion Date

June 1, 2027

Conditions
Non-alcoholic Steatohepatitis
Interventions
DRUG

PET scan of 68Ga-FAPI

Use of a positron emission tomograph equipped with an X-ray scanner (PET/CT), essential for recording images after injection of a positron-emitting radiopharmaceutical (in this study, 68Ga-FAPI-46).

All Listed Sponsors
lead

Central Hospital, Nancy, France

OTHER

NCT06160271 - Study of Liver Fibrosis Stage Assessment by Fibroblast Activation Protein Imaging in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis | Biotech Hunter | Biotech Hunter